2. Search Result
Search Result
Results for "

plasma cholesterol levels

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Inhibitory Antibodies

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121776
    Nicomol

    		Drug Derivative Cardiovascular Disease
    Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
    Nicomol
  • HY-137318
    BM 15766 sulfate

    		Others Metabolic Disease
    BM 15766 sulfate is an inhibitor of 7-dehydrocholesterol δ7-reductase and reduces plasma cholesterol levels. BM 15766 sulfate is a hypolipidemic agent .
    BM 15766 sulfate
  • HY-117549
    Ibrolipim

    NO-1886

    		 Lipase Cardiovascular Disease
    Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .
    Ibrolipim
  • HY-P99822
    Recaticimab

    SHR-1209

    		 PCSK9 LDLR Metabolic Disease
    Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
    Recaticimab
  • HY-100313A
    YM-53601
    3 Publications Verification

    		 Farnesyl Transferase HCV Infection Metabolic Disease
    YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601
  • HY-116150
    Xymedon

    		Others Cardiovascular Disease
    Xymedon is a pyrimidine derivative with anti-atherosclerotic effects. Xymedon reducts plasma cholesterol levels and cholesterol esterification in blood vascular cells .
    Xymedon
  • HY-N15293
    Sesamolinol

    		Others Metabolic Disease
    Sesamolinol is a lignin. Sesamolinol is found in sesame seeds. Sesame seed lignans are considered responsible for a number of beneficial health effects including lowering of plasma cholesterol levels and elevation of γ-tocopherol levels .
    Sesamolinol
  • HY-113086
    CE(16:1(9Z))

    16:1(9Z) CE; 16:1(9Z) cholesterol ester; cholesterol Palmitoleate

    		 Endogenous Metabolite Cardiovascular Disease
    Cholesteryl palmitoleate is a cholesterol ester. Plasma levels of cholesteryl palmitoleate are increased in ApoE-/- mice exposed to cigarette smoke and in pediatric patients with biliary atresia. Cholesteryl palmitoleate has been used as a standard for the identification of cholesterol esters in human meibomian gland secretions.
    CE(16:1(9Z))
  • HY-106938
    Eldacimibe

    WAY-ACA 147

    		 Acyltransferase Cardiovascular Disease Metabolic Disease
    Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
    Eldacimibe
  • HY-161939
    7030B-C5

    		PCSK9 Cardiovascular Disease
    7030B-C5 is a PCSK9 inhibitor (IC50=1.61 μM). 7030B-C5 can significantly reduce plasma cholesterol and triglyceride (TG) levels in vivo and slow the progression of atherosclerosis. 7030B-C5 can be used in the study of cardiovascular diseases .
    7030B-C5
  • HY-100313
    YM-53601 free base

    		Farnesyl Transferase HCV Metabolic Disease
    YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601 free base
  • HY-117912
    TRC210258

    		Endogenous Metabolite Cardiovascular Disease
    TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
    TRC210258
  • HY-161940
    PCSK9-IN-30

    		PCSK9 Cardiovascular Disease
    PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .
    PCSK9-IN-30
  • HY-145549
    C20 Sphingomyelin (d18:1/20:0)

    N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)

    		 Endogenous Metabolite Endocrinology
    C20 Sphingomyelin (d18:1/20:0) (N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)) is a naturally occurring sphingolipid. C20 Sphingomyelin (d18:1/20:0) levels are upregulated in the hippocampus of streptozotocin (HY-13753)-induced diabetic rats and in human plasma, positively correlating with insulin resistance in obese humans. C20 Sphingomyelin (d18:1/20:0) is also upregulated in the liver of a mouse model of Niemann-Pick C1 disease, a neurodegenerative cholesterol sphingolipid lysosomal storage disorder.
    C20 Sphingomyelin (d18:1/20:0)
  • HY-14998
    Halofenate

    MK 185

    		 β-catenin PPAR Wnt Endocrinology
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo .
    Halofenate
  • HY-137390A
    (3S,5R)-Fluvastatin potassium

    		HMG-CoA Reductase (HMGCR) Cardiovascular Disease Metabolic Disease
    (3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
    (3S,5R)-Fluvastatin potassium
  • HY-153830
    LacCer (d18:1/16:0)

    C16 Lactosylceramide (d18:1/16:0)

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .
    LacCer (d18:1/16:0)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: